BIOCRYST PHARMACEUTICALS Business Summary

BioCryst Pharmaceuticals (BCRX) operates as a commercial-stage biotechnology firm primarily generating revenue through the direct sale of proprietary small-molecule therapies, supplemented by licensing agreements and international royalties. The company’s financial engine is driven by its rare disease segment, specifically ORLADEYO (berotralstat), the first oral once-daily prophylactic for hereditary angioedema (HAE), which accounts for the vast majority of its $635M–$660M projected 2026 revenue. Following the late 2025 divestiture of its European operations to Neopharmed Gentili and the January 2026 acquisition of Astria Therapeutics, BioCryst has pivoted to a U.S.-centric model focused on high-margin orphan drug markets and its newly integrated navenibart program. Within the HAE landscape, BioCryst competes directly with Takeda (Takhzyro), CSL Behring (Haegarda), and Pharming Group (Ruconest), positioning itself as the market leader in oral prophylaxis by offering a non-invasive alternative to traditional injectable and infused therapies. BioCryst was founded in 1986 by William Spencer III, Dr. Charles Bugg, a renowned crystallography professor, and Dr. John Montgomery, a distinguished medicinal chemist. The leadership team is currently headed by CEO Charlie Gayer, who assumed the role in January 2026 after serving as the company’s Chief Commercial Officer and architect of the ORLADEYO launch; his background includes senior commercial roles at Talecris Biotherapeutics and Grifols. Supporting the executive suite are CFO Anthony Doyle, formerly of GE Healthcare, and Chief Discovery Officer Dr. Yarlagadda S. Babu, the company’s first employee and a key figure in its structure-guided drug design. The board is chaired by Vincent J. Milano, former CEO of Idera Pharmaceuticals and Synageva BioPharma, reflecting a high-pedigree governance structure. The company maintains a strong institutional investor base, with significant positions held by Orbimed Advisors, Vanguard Group, and Goldman Sachs.